Changes after publication
February 2014: implementation section updated to clarify that ranibizumab and pegaptanib are recommended as options for treating age-related macular degeneration. Additional minor maintenance update also carried out.
March 2012: minor maintenance
May 2012: re-issued after a change to the patient access scheme